Dianthus Therapeutics, INC. /De/ (DNTH) — SC 13D/A Filings

All SC 13D/A filings from Dianthus Therapeutics, INC. /De/. Browse 4 SC 13D/A reports with AI-powered summaries and risk analysis.

SC 13D/A Filings (4)

Avidity Partners Amends Stake in Dianthus Therapeutics — Dec 3, 2024 Risk: medium
Avidity Partners Management LP, through its filing on December 3, 2024, has amended its Schedule 13D regarding Dianthus Therapeutics, Inc. The filing indicates
Viridian LLC Amends Stake in Dianthus Therapeutics — Sep 12, 2024 Risk: medium
Viridian, LLC, a significant shareholder, filed an amendment to its Schedule 13D on September 12, 2024, regarding its holdings in Dianthus Therapeutics, Inc. Th
Fairmount Funds Adjusts Stake in Dianthus Therapeutics — Apr 1, 2024 Risk: medium
Fairmount Funds Management LLC, through its affiliated entities and individuals Peter Harwin and Tomas Kiselak, has amended its Schedule 13D filing concerning D
Fairmount Funds Management Amends 13D for Dianthus Therapeutics — Jan 24, 2024
Fairmount Funds Management LLC, along with its affiliated funds (Fairmount Healthcare Fund II LP, Fairmount Healthcare Fund LP, and Fairmount SPV III, LLC) and

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX